Oral GLP‑1 pill approved
- The FDA approved oral semaglutide as the first GLP‑1 pill authorized specifically for weight‑loss treatment. - The pill offers an alternative format to injectable GLP‑1s like Wegovy for people seeking weight management options. - Policymakers and programs are debating access and cost while Medicare/Medicaid pilots and demonstration ideas move in different directions ( ).
The Food and Drug Administration has cleared Wegovy tablets, making semaglutide the first oral glucagon-like peptide-1 drug approved in the U.S. for chronic weight management. (accessdata.fda.gov) The label says the tablet is indicated, with diet and exercise, for adults with obesity or adults who are overweight and have at least one weight-related condition. It also carries a cardiovascular indication for adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) Semaglutide is a glucagon-like peptide-1, or GLP-1, receptor agonist: it copies a gut hormone that helps regulate appetite and blood sugar. For years, the weight-loss versions were best known as weekly shots, including injectable Wegovy. (novonordisk.com, fda.gov) Turning that kind of drug into a pill was difficult because stomach acid and digestive enzymes break down protein-based medicines the way they break down food. Novo Nordisk says oral semaglutide for type 2 diabetes reached the U.S. market in 2019, and the weight-management version was approved in 2025. (novonordisk.com) In the OASIS 4 trial cited by AJMC, adults taking oral semaglutide lost an average of 13.6% of body weight at 64 weeks, versus 2.2% with placebo. The study enrolled 307 adults with obesity or overweight and no diabetes. (ajmc.com) The Food and Drug Administration label also describes a placebo-controlled tablet study with 204 adults with obesity or overweight and at least one weight-related condition who were treated for up to 64 weeks. The approved tablet strength is 25 milligrams taken once daily. (accessdata.fda.gov) The approval lands in the middle of a coverage fight. KFF says current law still bars Medicare from covering drugs used for weight loss, while Medicaid programs can choose whether to cover them under a long-standing exception for weight-loss drugs. (kff.org, kff.org) In March, KFF reported that the Centers for Medicare & Medicaid Services had set up a temporary 2026 Medicare GLP-1 Bridge program with a $50 copayment for eligible beneficiaries from July 1 through December 31, 2026. On April 21, KFF said CMS then announced that the BALANCE Model would not launch in Medicare Part D in 2027 as originally planned and that the Bridge program would be extended through 2027. (kff.org, kff.org) KFF also found that 56% of GLP-1 users said the drugs were difficult to afford, including one in four who called them “very difficult” to afford. That leaves the new pill arriving with a second question beyond convenience: who will actually be able to get it. (kff.org)
